We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Redhill Biopharma Ltd | NASDAQ:RDHL | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.0007 | -0.16% | 0.4498 | 0.30 | 0.93 | 0.4674 | 0.4498 | 0.4674 | 173,901 | 05:00:05 |
From May 2021 to May 2024
By Michael Dabaie
RedHill Biopharma Ltd. said an analysis showed its oral opaganib reduces mortality by 70% given on top of remdesivir and corticosteroids in severe Covid-19.
The company said its prespecified analysis of Phase 2/3 opaganib data in severe Covid-19 patients showed a significant, 70.2% mortality benefit with opaganib by day 42 when given on top of the best available standard-of-care, remdesivir and corticosteroids.
A second analysis showed that opaganib also delivered a significant 34% benefit in time to recovery by day 14, with 37.4% of opaganib-treated patients reaching this event versus 27.9% of patients treated with placebo plus standard of care.
RedHill said it is advancing regulatory discussions in multiple countries, with potential emergency and marketing authorization applications being planned for certain countries in the first half of 2022.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
February 07, 2022 11:01 ET (16:01 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Redhill Biopharma Chart |
1 Month Redhill Biopharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
